

Sanofi  
Form 6-K  
October 25, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 6-K**  
**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of October 2011

Commission File Number: 001-31368

**SANOFI**

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F                       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes     No

If "Yes" marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

In October 2011, Sanofi issued the press releases attached hereto as Exhibits 99.1 to 99.4 which are incorporated herein by reference.

**Exhibit List**

Exhibit No.	<u>Description</u>
Exhibit 99.1	Press release dated October 05, 2011: Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio ) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity
Exhibit 99.2	Press release dated October 18, 2011: Sanofi and its subsidiary Genzyme to Feature More than 20 Data Presentations at theECTRIMS/ACTRIMS Congress
Exhibit 99.3	Press release dated October 20, 2011: Oral Therapy Teriflunomide (Aubagio ) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
Exhibit 99.4	Press release dated October 22, 2011: Alemtuzumab (Lemtrada ) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 25, 2011

SANOFI

By           /S/          John Felitti            
Name: John Felitti  
Title: Associate Vice President,  
Corporate Law, Financial &  
  
Securities Law

**Exhibit Index**

<b>Exhibit No.</b>	<b><u>Description</u></b>
Exhibit 99.1	Press release dated October 05, 2011: Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio ) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity
Exhibit 99.2	Press release dated October 18, 2011: Sanofi and its subsidiary Genzyme to Feature More than 20 Data Presentations at theECTRIMS/ACTRIMS Congress
Exhibit 99.3	Press release dated October 20, 2011: Oral Therapy Teriflunomide (Aubagio ) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
Exhibit 99.4	Press release dated October 22, 2011: Alemtuzumab (Lemtrada ) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study